---
title: "Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics"
description: Medical diagnostics pioneer Proteomics International Laboratories has filled its pockets with a further $2.2 million in cash through Australia’s research and development (R&D) rebate scheme.
---

[News & Media ](https://www.proteomics.com.au/news-media)

# [Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics](https://www.proteomics.com.au/news-media/bell-financial-groups-grady-wulff-speaks-with-proteomics-international-laboratories-asx-piq-ceo-dr.-richard-lipscombe-about-the-companys-ground-breaki-1767959732064)

 Written by [Proteomics](https://www.proteomics.com.au/news-media/author/proteomics) | Jan 9, 2026, 11:56:13 AM

In this [episode of from the helm](https://www.belldirect.com.au/smarter/insights/podcasts/from-the-helm-proteomics-international-asxpiq-dr-richard-lipscombe-managing-director), Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:  
·      (0:47): An overview of PIQ and its FY26 goals  
·      (1:38): The significance of three world-first blood tests  
·      (5:26): The global addressable markets for these conditions  
·      (6:25): Clinical trial progress and commercialisation roadmap  
·      (8:14): How the diagnostic tests work and deliver value to patients  
·      (9:16): Commercialisation strategy across key regions  
·      (11:23): Additional assets in the PIQ pipeline  
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

View interview [here](https://www.belldirect.com.au/smarter/insights/podcasts/from-the-helm-proteomics-international-asxpiq-dr-richard-lipscombe-managing-director)  |   [Listen on Spotify](https://open.spotify.com/episode/4UTYA0id8VQmV0hqO8osdL?si=TOmpW2e7RKSU1vWvqh_-ow)   |   [Podcast download](https://www.proteomics.com.au/hubfs/Content_Asset_Management/Investor_Docs/08_media_releases/From%20the%20Helm%20podcast.mp3)

[View full post](https://www.proteomics.com.au/news-media/bell-financial-groups-grady-wulff-speaks-with-proteomics-international-laboratories-asx-piq-ceo-dr.-richard-lipscombe-about-the-companys-ground-breaki-1767959732064)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Proteomics"
  },
  "dateModified" : "2026-07-30T06:03:37.353Z",
  "datePublished" : "2026-01-09T11:56:13Z",
  "headline" : "Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics",
  "image" : {
    "@type" : "ImageObject",
    "height" : 60,
    "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
    "width" : 60
  },
  "mainEntityOfPage" : "https://www.proteomics.com.au/news-media/bell-financial-groups-grady-wulff-speaks-with-proteomics-international-laboratories-asx-piq-ceo-dr.-richard-lipscombe-about-the-companys-ground-breaki-1767959732064",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "News & Media"
  }
}
```